PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

Launched by PROCEPT BIOROBOTICS · Sep 18, 2023

Keywords

ClinConnect Summary

The PRCT001 clinical trial is studying a new treatment option called the AQUABEAM Robotic System, which is designed to remove prostate tissue in men who have localized prostate cancer and are experiencing lower urinary tract symptoms (like trouble urinating). The goal of the trial is to evaluate how well this robotic system works and to ensure it is safe for patients. If you are a male patient with specific symptoms and a certain level of prostate cancer (Gleason Grade Group 1-3), you may be eligible to participate.

Eligible participants will have their symptoms and health monitored before starting the treatment and then again over the next 12 months. The trial is currently looking for participants, but it's important to note that those who have had previous surgery for prostate issues or have more advanced cancer may not qualify. This trial aims to provide insights into a potentially effective treatment for prostate cancer while also improving urinary symptoms for those affected.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • International Prostate Symptom Score (IPSS) ≥ 8
• • Gleason Grade Group 1-3
• • Prostate-specific Antigen (PSA) ≤20ng/mL
• • Cancer stage less than or equal to T2c
• Exclusion Criteria:
• • Patients with previous surgical treatment of benign prostatic hyperplasia
• • MRI evidence of extracapsular extension of cancer
• • Any severe illness that would prevent complete study participation or confound study results